A citation-based method for searching scientific literature

William B White, Kenneth G Saag, Michael A Becker, Jeffrey S Borer, Philip B Gorelick, Andrew Whelton, Barbara Hunt, Majin Castillo, Lhanoo Gunawardhana. N Engl J Med 2018
Times Cited: 272







List of co-cited articles
833 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Michael A Becker, H Ralph Schumacher, Robert L Wortmann, Patricia A MacDonald, Denise Eustace, William A Palo, Janet Streit, Nancy Joseph-Ridge. N Engl J Med 2005
745
23

2016 updated EULAR evidence-based recommendations for the management of gout.
P Richette, M Doherty, E Pascual, V Barskova, F Becce, J Castañeda-Sanabria, M Coyfish, S Guillo, T L Jansen, H Janssens,[...]. Ann Rheum Dis 2017
530
23

Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
Isla S Mackenzie, Ian Ford, George Nuki, Jesper Hallas, Christopher J Hawkey, John Webster, Stuart H Ralston, Matthew Walters, Michele Robertson, Raffaele De Caterina,[...]. Lancet 2020
33
69

Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
Kenjiro Kimura, Tatsuo Hosoya, Shunya Uchida, Masaaki Inaba, Hirofumi Makino, Shoichi Maruyama, Sadayoshi Ito, Tetsuya Yamamoto, Yasuhiko Tomino, Iwao Ohno,[...]. Am J Kidney Dis 2018
111
22

Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy.
Sunao Kojima, Kunihiko Matsui, Shinya Hiramitsu, Ichiro Hisatome, Masako Waki, Kazuaki Uchiyama, Naoto Yokota, Eiichi Tokutake, Yutaka Wakasa, Hideaki Jinnouchi,[...]. Eur Heart J 2019
67
29

Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study.
Michael M Givertz, Kevin J Anstrom, Margaret M Redfield, Anita Deswal, Haissam Haddad, Javed Butler, W H Wilson Tang, Mark E Dunlap, Martin M LeWinter, Douglas L Mann,[...]. Circulation 2015
152
17

Effect of allopurinol in chronic kidney disease progression and cardiovascular risk.
Marian Goicoechea, Soledad García de Vinuesa, Ursula Verdalles, Caridad Ruiz-Caro, Jara Ampuero, Abraham Rincón, David Arroyo, José Luño. Clin J Am Soc Nephrol 2010
514
15


Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials.
Markus Bredemeier, Lediane Moreira Lopes, Matheus Augusto Eisenreich, Sheila Hickmann, Guilherme Kopik Bongiorno, Rui d'Avila, André Luis Bittencourt Morsch, Fernando da Silva Stein, Guilherme Gomes Dias Campos. BMC Cardiovasc Disord 2018
69
21

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
H Ralph Schumacher, Michael A Becker, Robert L Wortmann, Patricia A Macdonald, Barbara Hunt, Janet Streit, Christopher Lademacher, Nancy Joseph-Ridge. Arthritis Rheum 2008
366
15

2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.
Dinesh Khanna, John D Fitzgerald, Puja P Khanna, Sangmee Bae, Manjit K Singh, Tuhina Neogi, Michael H Pillinger, Joan Merill, Susan Lee, Shraddha Prakash,[...]. Arthritis Care Res (Hoboken) 2012
954
14

Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study.
MaryAnn Zhang, Daniel H Solomon, Rishi J Desai, Eun Ha Kang, Jun Liu, Tuhina Neogi, Seoyoung C Kim. Circulation 2018
50
26

Uric acid and cardiovascular risk.
Daniel I Feig, Duk-Hee Kang, Richard J Johnson. N Engl J Med 2008
12

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.
Michael A Becker, H Ralph Schumacher, Luis R Espinoza, Alvin F Wells, Patricia MacDonald, Eric Lloyd, Christopher Lademacher. Arthritis Res Ther 2010
305
11


Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
Yui-Pong Siu, Kay-Tai Leung, Matthew Ka-Hang Tong, Tze-Hoi Kwan. Am J Kidney Dis 2006
543
10

Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout.
Tatsuo Hosoya, Iwao Ohno, Shinsuke Nomura, Ichiro Hisatome, Shunya Uchida, Shin Fujimori, Tetsuya Yamamoto, Shigeko Hara. Clin Exp Nephrol 2014
77
12


Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial.
Marian Goicoechea, Soledad Garcia de Vinuesa, Ursula Verdalles, Eduardo Verde, Nicolas Macias, Alba Santos, Ana Pérez de Jose, Santiago Cedeño, Tania Linares, Jose Luño. Am J Kidney Dis 2015
162
10

Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study.
Joshua M Hare, Brian Mangal, Joanne Brown, Charles Fisher, Ronald Freudenberger, Wilson S Colucci, Douglas L Mann, Peter Liu, Michael M Givertz, Richard P Schwarz. J Am Coll Cardiol 2008
256
10

Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study).
Kenneth G Saag, David Fitz-Patrick, Jeff Kopicko, Maple Fung, Nihar Bhakta, Scott Adler, Chris Storgard, Scott Baumgartner, Michael A Becker. Arthritis Rheumatol 2017
103
10


Decreased extra-renal urate excretion is a common cause of hyperuricemia.
Kimiyoshi Ichida, Hirotaka Matsuo, Tappei Takada, Akiyoshi Nakayama, Keizo Murakami, Toru Shimizu, Yoshihide Yamanashi, Hiroshi Kasuga, Hiroshi Nakashima, Takahiro Nakamura,[...]. Nat Commun 2012
274
10

Global epidemiology of gout: prevalence, incidence and risk factors.
Chang-Fu Kuo, Matthew J Grainge, Weiya Zhang, Michael Doherty. Nat Rev Rheumatol 2015
480
9

Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study.
B F Culleton, M G Larson, W B Kannel, D Levy. Ann Intern Med 1999
827
9


Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).
Thomas Bardin, Robert T Keenan, Puja P Khanna, Jeff Kopicko, Maple Fung, Nihar Bhakta, Scott Adler, Chris Storgard, Scott Baumgartner, Alexander So. Ann Rheum Dis 2017
85
10

Regulation of uric acid metabolism and excretion.
Jessica Maiuolo, Francesca Oppedisano, Santo Gratteri, Carolina Muscoli, Vincenzo Mollace. Int J Cardiol 2016
320
9

Gout-associated uric acid crystals activate the NALP3 inflammasome.
Fabio Martinon, Virginie Pétrilli, Annick Mayor, Aubry Tardivel, Jürg Tschopp. Nature 2006
8

Uric acid and risk of heart failure: a systematic review and meta-analysis.
He Huang, Baotao Huang, Yulin Li, Yan Huang, Jing Li, Hongmei Yao, Xianchao Jing, Jianrong Chen, Ji Wang. Eur J Heart Fail 2014
133
8

Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study.
Anne-Kathrin Tausche, Rieke Alten, Nicola Dalbeth, Jeff Kopicko, Maple Fung, Scott Adler, Nihar Bhakta, Chris Storgard, Scott Baumgartner, Kenneth Saag. Rheumatology (Oxford) 2017
51
15

Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies.
Wolfram Doehner, Nina Schoene, Mathias Rauchhaus, Francisco Leyva-Leon, Darrell V Pavitt, David A Reaveley, Gerhard Schuler, Andrew J S Coats, Stefan D Anker, Rainer Hambrecht. Circulation 2002
419
8

High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid.
Jacob George, Elaine Carr, Justine Davies, J J F Belch, Allan Struthers. Circulation 2006
391
8

Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism.
M Mazzali, J Hughes, Y G Kim, J A Jefferson, D H Kang, K L Gordon, H Y Lan, S Kivlighn, R J Johnson. Hypertension 2001
827
8

2020 American College of Rheumatology Guideline for the Management of Gout.
John D FitzGerald, Nicola Dalbeth, Ted Mikuls, Romina Brignardello-Petersen, Gordon Guyatt, Aryeh M Abeles, Allan C Gelber, Leslie R Harrold, Dinesh Khanna, Charles King,[...]. Arthritis Care Res (Hoboken) 2020
67
11

Effects of Allopurinol on the Progression of Chronic Kidney Disease.
Sunil V Badve, Elaine M Pascoe, Anushree Tiku, Neil Boudville, Fiona G Brown, Alan Cass, Philip Clarke, Nicola Dalbeth, Richard O Day, Janak R de Zoysa,[...]. N Engl J Med 2020
84
9

Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes.
Alessandro Doria, Andrzej T Galecki, Cathie Spino, Rodica Pop-Busui, David Z Cherney, Ildiko Lingvay, Afshin Parsa, Peter Rossing, Ronald J Sigal, Maryam Afkarian,[...]. N Engl J Med 2020
69
11

Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?
Richard J Johnson, Duk-Hee Kang, Daniel Feig, Salah Kivlighn, John Kanellis, Susumu Watanabe, Katherine R Tuttle, Bernardo Rodriguez-Iturbe, Jaime Herrera-Acosta, Marilda Mazzali. Hypertension 2003
846
7

Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial.
Michael Doherty, Wendy Jenkins, Helen Richardson, Aliya Sarmanova, Abhishek Abhishek, Deborah Ashton, Christine Barclay, Sally Doherty, Lelia Duley, Rachael Hatton,[...]. Lancet 2018
86
8

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.
Shuen-Iu Hung, Wen-Hung Chung, Lieh-Bang Liou, Chen-Chung Chu, Marie Lin, Hsien-Ping Huang, Yen-Ling Lin, Joung-Liang Lan, Li-Cheng Yang, Hong-Shang Hong,[...]. Proc Natl Acad Sci U S A 2005
779
7

Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial).
Akira Sezai, Masayoshi Soma, Kin-ichi Nakata, Mitsumasa Hata, Isamu Yoshitake, Shinji Wakui, Hiroaki Hata, Motomi Shiono. Circ J 2013
76
9

Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial.
Dipankar Sircar, Soumya Chatterjee, Rajesh Waikhom, Vishal Golay, Arpita Raychaudhury, Suparna Chatterjee, Rajendra Pandey. Am J Kidney Dis 2015
147
7

Elevated uric acid increases the risk for kidney disease.
Rudolf P Obermayr, Christian Temml, Georg Gutjahr, Maarten Knechtelsdorfer, Rainer Oberbauer, Renate Klauser-Braun. J Am Soc Nephrol 2008
366
7


Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study.
Kazuhide Ogino, Masahiko Kato, Yoshiyuki Furuse, Yoshiharu Kinugasa, Katsunori Ishida, Shuichi Osaki, Toru Kinugawa, Osamu Igawa, Ichiro Hisatome, Chiaki Shigemasa,[...]. Circ Heart Fail 2010
124
7

Effect of Allopurinol on Cardiovascular Outcomes in Hyperuricemic Patients: A Cohort Study.
Kasper Søltoft Larsen, Anton Pottegård, Hanne M Lindegaard, Jesper Hallas. Am J Med 2016
43
16

Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study.
Isla S Mackenzie, Ian Ford, Andrew Walker, Chris Hawkey, Alan Begg, Anthony Avery, Jaspal Taggar, Li Wei, Allan D Struthers, Thomas M MacDonald. BMJ Open 2016
39
17

Hyperuricemia and incident hypertension: a systematic review and meta-analysis.
Peter C Grayson, Seo Young Kim, Michael LaValley, Hyon K Choi. Arthritis Care Res (Hoboken) 2011
393
7

Effects of uric acid-lowering therapy in patients with chronic kidney disease: A meta-analysis.
Xiaole Su, Boyang Xu, Bingjuan Yan, Xi Qiao, Lihua Wang. PLoS One 2017
43
16

A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout.
Lisa K Stamp, Peter T Chapman, Murray L Barclay, Anne Horne, Christopher Frampton, Paul Tan, Jill Drake, Nicola Dalbeth. Ann Rheum Dis 2017
57
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.